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Abstract
Introduction The GREENFIELD observational study assessed the effect of levodopa/carbidopa intestinal gel (LCIG) on 
motor and non-motor symptoms, and the related impact on patient quality of life and caregiver burden up to 8 years.
Methods Final results of a large Italian cohort of patients who started LCIG in routine care between 2007 and 2014 are 
presented. Comparison between baseline (before LCIG) and follow-up visits on yearly basis (visit 2/3) is reported. Primary 
endpoint was Unified Parkinson’s Disease Rating Scale (UPDRS-IV) Item 39; secondary endpoints were UPDRS I and II, 
dyskinesia items, PD Quality of Life Questionnaire-39, Parkinson’s Disease Sleep Scale-2, Gait and Falls Questionnaire, 
Questionnaire on Impulsive Disorders, and Relative Stress Scale.
Results Overall, 145 patients from 14 centers were assessed with a mean time since LCIG start of 2.8 ± 1.7 years at visit 
2. The mean UPDRS-IV item 39 score showed significant reductions compared to baseline (mean score 2.0 ± 0.81) at visit 
2 (mean score 0.9 ± 0.69; − 55%; p < 0.001) and at visit 3 (mean score 1.0 ± 0.75; − 50%; p < 0.001). At visit 3, significant 
reductions were observed for dyskinesia duration score (− 28%; p < 0.001), dyskinesia disability (− 40%; p < 0.001), and 
painful dyskinesia (− 50%; p < 0.001). Overall, 40 (27.6%) patients experienced 49 serious adverse events which were con-
sidered related to PEG/J procedure or to device in 16.3% of the cases.
Conclusions The results of this study support the long-term efficacy of LCIG on PD symptoms as well as on activities of 
daily living. The adverse events were consistent with the established LCIG safety profile.
Keywords Advanced Parkinson’s disease · Levodopa/carbidopa · Intestinal infusion · Motor symptoms · Quality of life · 
Routine patient care
Introduction
Parkinson’s disease (PD) is a chronic, progressive neurode-
generative disorder characterized by motor and non-motor 
symptoms that impair patient’s autonomy and quality of life 
(QoL), together with a consequent burden also on caregiver 
QoL [1].
Oral levodopa efficacy shortens as PD progresses; in fact, 
within 2–5 years up to 50% of patients already may experi-
ence some degree of motor complications, with 80–100% of 
PD patients developing motor complications after 10 years 
of dopaminergic therapy. This is mainly due to the progres-
sive loss of striatal dopamine nerve terminals, the short levo-
dopa half-life, the delayed gastric emptying and abnormal 
intestinal absorption [2–4].
Levodopa/carbidopa intestinal gel (LCIG) is continuously 
delivered via a percutaneous endoscopic gastrostomy with 
a jejunal extension (PEG-J) providing a more stable plasma 
concentration in patients with non-optimal control of motor 
fluctuations [5].
Initial evidence for the efficacy and tolerability of 
LCIG came from a number of small-sample studies.[6, 7]. 
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Recently, three randomized clinical trials (RCTs) (one of 
them double blinded) have confirmed that LCIG reduced 
OFF time, increased ON time without increasing trouble-
some dyskinesias, and improved QoL [8–10]. The anti-
dyskinetic effect of LCIG has been reported in the post hoc 
analyses of a 12-week double-blind study and of a 54-week 
open-label study on patients having at least 1 h per day of 
ON-time with troublesome dyskinesia [11]. Recently, a 
6-month open-label pilot study, showing a 47% reduction 
of ON-time with troublesome dyskinesia, stated that LCIG 
has a substantial antidyskinetic effect and could be an alter-
native treatment also for PD patients with dyskinesia.[12].
Moreover, LCIG leads to significant improvements in 
motor and non-motor symptoms, in daily living activities 
and QoL also in patients with motor complications [13].
The long-term effectiveness of levodopa/carbidopa in 
APD patients on motor complications and QoL has been 
assessed in several routine clinical care studies up to 4 years 
of treatment duration [14–19]. Few studies have been con-
ducted in large populations to assess the LCIG outcomes 
longer than 4 years [20, 21]. Therefore, in the current study, 
we recorded the clinical outcomes in a large cohort of APD 
patients receiving LCIG in routine clinical care to evaluate 
the effects of therapy on both motor and non-motor symp-
toms, and the related impact on patient QoL and caregiver 
burden from the initiation of LCIG therapy over a maxi-
mum exposure period up to 8 years. The interim analysis of 
this study comparing the changes in primary endpoint and 
UPDRS scores between visit 1 (V1) and baseline (BL) data 
was previously published [22]. Here, we present the final 
results of this study.
Patients and methods
This post-marketing observational study was conducted in 
14 Italian Movement Disorder Centers.
Treatment with LCIG was initiated in a routine patient 
care setting, according to the Summary of Product Charac-
teristics, including the temporary naso-jejunal (NJ) phase to 
determine if the patient responded favorably to LCIG and to 
optimize the dose before treatment was initiated via PEG-J 
tube.
Patient selection
Consecutive APD patients showing motor fluctuations 
despite the use of oral medication, who started LCIG infu-
sion according to clinical practice between 2007 and 2014, 
were considered eligible for enrollment into the study.
Inclusion criteria were: to be already treated with LCIG, 
presence of adequate information about previous medical 
history and treatment, and presence of at least one fulfilled 
scale or questionnaire among those collected during the 
study. Patients could be enrolled at any time after LCIG 
treatment initiation. Exclusion criteria were the presence of 
any conditions that, at the physician’s discretion, could inter-
fere with the long-term treatment with LCIG.
At the enrollment visit (V1), patient history and retro-
spective clinical data referred to previous conventional PD 
treatment, NJ phase and initiation of LCIG treatment via 
PEG-J were collected as BL data. During the same visit, 
current clinical parameters were also collected as V1 data. 
For the analysis, BL was defined as the last available data 
collected prior to NJ tube positioning.
Study design and treatment
The study design included two patient populations: the ret-
rospective population and the prospective population. The 
retrospective population included all patients who had been 
receiving treatment with LCIG for ≥ 1 year and up to 7 years 
before V1, with available BL retrospective assessment data 
for ≥ 1 year. The prospective population included all patients 
receiving treatment with LCIG for < 1 year before V1. 
Patients continuing with LCIG treatment for further 2 years 
after enrolment and with follow-up visits on yearly basis 
(visit 2, V2 and visit 3, V3 or at the last available visit) were 
included in the final analysis.
Assessments
Effectiveness
The primary endpoint was the change from baseline to the 
last available follow-up (V2 or V3 or the last available visit) 
in the item-39 of the UPDRS-IV (proportion of waking day 
spent in OFF).
At V1 (enrolment visit), the following baseline data for 
secondary effectiveness measures were collected: demo-
graphics, medical history, previous PD treatments, NJ 
phase, LCIG dose of infusion at discharge from the hospi-
tal; the Hoehn and Yahr scale; the UPDRS I total score (in 
ON and OFF conditions), activities of daily living (ADL), 
as assessed by means of the UPDRS II total score (in ON 
and OFF conditions), UPDRS IV (total score), and items for 
dyskinesia duration (Item 32), dyskinesia severity (Item 33), 
painful dyskinesia (Item 34), and early-morning dystonia 
(Item 35). At the same visit, PD Quality of Life Question-
naire (PDQ-39), Parkinson’s Disease Sleep Scale (PDSS-
2), Gait and Falls Questionnaire (GFQ), Questionnaire on 
Impulsive Disorders (QUIP-RS), and the Relative Stress 
Scale (RSS) for caregiver burden assessment were collected 
only for patients in treatment with LCIG for more than 1 
year before the enrolment visit and for all patients with miss-
ing BL value.
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The same assessments were repeated at V2 and at V3 
including concurrent diseases and therapies, dosages and 
changes in LCIG daily infusion, and the economic and social 
impact of the familiar caregiver assistance. At each visit, the 
global efficacy on motor symptoms was rated by neurolo-
gist versus baseline by a three-point scale: improvement, no 
change, worsening. The patient’s judgment on LCIG benefit, 
was collected at each visit by means of a scale rating from 
0 to 10 and grouped as follows: 0–2 very bad, 3–5 unsatis-
factory, 6–8 satisfactory, 9–10 very good. Safety data were 
collected from enrolment visit onward.
Safety
Serious adverse events (SAE) were collected retrospec-
tively at the enrolment visit (V1) and prospectively at each 
follow-up visit (V2 and V3). Adverse events (AE) were 
prospectively collected. Furthermore, all the Product Qual-
ity Complaints (PQC), with regard to the medical devices 
defined as communication that alleges deficiencies related 
to the identity, physical aspects, potency, expressed lack of 
effect, purity, packaging, durability, reliability, safety or per-
formance, associated or not with an AE were retrospectively 
and prospectively collected.
Statistical analysis
Sample size evaluation
Postulating a correlation between values at baseline and at 
last follow-up = 0 (conservative decision), a mean differ-
ence between baseline and last follow-up on the item 39 
of UPDRS questionnaire of – 1.0, a SD of 2.0 and using 
a paired t test, 87 subjects were to be enrolled, with two-
sided significance level = 5% and power = 90%. Consider-
ing a drop-out rate of 40% (according to the Italian clinical 
experience: 22% of drop-outs + 18% of deaths should be 
considered), at least 145 subjects were needed; therefore, a 
total of 150 patients were estimated to be enrolled.
Statistical analysis
All statistical analyses were carried out by means of the 
SAS® package (version 9.2). Continuous and categorical 
variables were summarized by descriptive statistics. Statisti-
cal significance was declared if the rounded p value was less 
than or equal to 0.05.
All patients from enrolled population that performed 
at least one post-baseline visit (V2 or V3 for prospective 
patients, V1 or V2 or V3 for retrospective patients) were 
included in the evaluable population. All analyses of efficacy 
variables were performed in the evaluable population.
For assessments over time (e.g., for all rating scales), the 
analysis by visit (V1–V3) was complemented by an analysis 
according to the “last-observation-carried-forward” (LOCF) 
principle: missing data at V3 have been replaced with the 
(non-missing) data recorded at V2. No baseline value (at V1) 
has been considered in the LOCF technique.
Comparisons between BL and each follow-up visit (with 
LOCF) of the efficacy endpoints were performed using a 
paired t test. Comparison between BL and each follow-up 
visit (with LOCF) of item 35 of UPDRS was performed by 
means of McNemar test. The same analysis was performed 
separately for the subgroups of prospective and retrospec-
tive patients. The comparison of the clinical indexes and 
the questionnaires scores during time was also confirmed 
through ANOVA for repeated measures on the population 
without LOCF.
To evaluate the impact of age of the patient and dura-
tion of disease on the UPDRS scores, a secondary analy-
sis was performed by means of an analysis of covariance 
(ANCOVA) model with change from BL (with LOCF) as 
dependent variable, age of patient (dichotomous varia-
ble: ≤ 70 years; > 70 years), time since PD diagnosis (dichot-
omous variable: ≤ 13 years; > 13 years), and time since infu-
sion ( < 1 year vs ≥ 1 year) as fixed effects and BL value as 
covariate. The difference between the adjusted means for 
age ≤ 70 years versus > 70 years and for time since PD diag-
nosis ≤ 13 years versus > 13 years were calculated with the 
associated 95% CI and p value.
Results
From the start of enrollment in November 2012 through 
July 2014, a total of 148 patients were included among the 
participating centers. Three subjects were excluded, due to 
inclusion/exclusion criteria violation, so the enrolled sam-
ple consists of 145 patients and 137 were evaluable. Across 
the study, 30 patients discontinued for different reasons and 
115 patients completed the 24-month follow-up (Fig. 1). 
Considering that no differences in the primary and second-
ary efficacy measures were found between the retrospective 
(N = 59) and prospective populations (N = 86; 78 evaluable), 
we present here the results of the total population. In the 
total evaluable population, BL values were the data recorded 
before naso-jejunal phase or, if missing, data recorded at V1.
Demographic, medical history, occupational status, and 
previous advanced PD medications before the initiation of 
LCIG are summarized in Table 1. The mean age of patients 
( ± SD) was 70.4 ± 7.7 years, and the mean PD duration and 
the mean time since the onset of motor fluctuations were, 
respectively, 14.6 ± 6.5 and 5.9 ± 3.9 years.
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The antiparkinsonian medications with the daily dosages 
prior to start LCIG infusion are reported in Table 2; oral 
levodopa was the most commonly used antiparkinsonian 
medication (96.6% of patients), at a mean daily dose of 
818.17 ± 404.4 mg.
The primary reasons to switch from oral antiparkinso-
nian therapy to LCIG were disabling OFF periods in 115 
patients (79%) and uncontrolled dyskinesia in 32 patients 
(25%). At the last visit, the mean time since the LCIG start 
was 2.8 ± 1.66 years with a maximum treatment period of 
8 years. The mean continuous infusion rate at the discharge 
from hospital was 3.21 ± 1.09 ml/h and it remained stable at 
the following visits (respectively, 3.23 ± 1.03 and 3.31 ± 1.28 
at V2 and V3). LCIG was infused for 16 h per day, while 
only one patient at V1 and three patients at V3 reported a 
24-h infusion.
Efficacy
The mean UPDRS-IV item 39 score showed significant and 
sustained reductions at V2 compared to BL (mean BL score 
2.0 ± 0.81, mean V2 score 0.9 ± 0.69; − 55%; p < 0.001) 
and also compared to V3 (mean score 1.0 ± 0.75; − 50%; 
p < 0.001), as reported in Fig. 2.
Furthermore, at each visit, respectively, 83% and 78% of 
the patients showed less than 25% of daily time spent in OFF 
while at BL the majority of them (76%) had more than 25% 
of daily time in OFF (Fig. 3).
The mean LCIG treatment period at the primary end-
point assessment (V3) was 3.1 ± 1.5  years in the gen-
eral population, while in the retrospective population the 
mean LCIG treatment period was 3.7 ± 1.7 years at V2 and 
4.5 ± 1.5 years at V3.
At the last follow-up visit (V3), significant reductions 
compared to BL were observed for dyskinesia duration score 
(− 28% UPDRS IV Item 32; p < 0.001), dyskinesia disability 
(− 40% UPDRS IV Item 33; p < 0.001), and painful dyski-
nesia (− 50% UPDRS IV Item 34; p < 0.001) with a similar 
trend at each follow-up visit. The mean score reductions for 
each of the above-mentioned parameters and the correspond-
ing p values are reported in Table 3, along with the ANOVA 
results for repeated measures.
The UPDRS-IV (Part A + B) was significantly reduced 
compared to BL (mean baseline score 8.2 ± 3.27) both at V2 
(mean score 4.7 ± 2.88; p < 0.001) and at V3 (mean score 
4.9 ± 3.12; p < 0.001).
Twenty-five percent of the patients reported early morn-
ing dystonia (UPDRS IV Item 35) at V3 while this percent-
age was higher at BL (44% of the patients, p < 0.001).
There was a significant improvement through the whole 
study duration, on UPDRS II in OFF state that was reduced 
from 29.2 ± 9.63 at BL to 25.7 ± 8.49 (p < 0.001) at V2 and 
to 25.5 ± 8.76 at V3 (p = 0.003) (Table 3).
Fig. 1  Patient disposition
Table 1  Demographic and clinical characteristics of the study popu-
lation
Parameters Value Range
Demographics n = 145
 Gender
  Female, n (%) 72 (49.7%)
  Male, n (%) 73 (50.3%)
 Age (years) 70.4 ± 7.7 49–90
 Age
   < 65 years, n (%) 30 (20.7%)
   ≥ 65 years, n (%) 115 (79.3%)
 Age > 70 years, n (%) 78 (53.8%)
PD medical history
 Age at PD diagnosis (years) 55.7 ± 9.27
 PD duration (years) 14.61 ± 6.58 1.3–46.7
 PD duration ≤ 13 years 72 (49.7%)
 PD duration > 13 years 73 (50.3%)
 Time since onset of motor 
fluctuations (years) 
(n = 143) (mean ± SD)
5.9 ± 4.0 1–21
 Previous use of invasive 
treatments (before LCIG 
infusion)
N(%) Daily dose, mean ± SD
 Previous deep brain stimula-
tion
3 (2.1%) NA
 Apomorphine SC (pump) 
(mg)
14 (9.7%) 86.29 (46.38)
 Apomorphine stylo (mg) 7 (4.8%) 6.5 (10.6)
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Quality-of-life and PD-associated symptoms
The results on QoL and PD-associated symptoms ques-
tionnaires at each visit showed a different behavior in the 
retrospective and prospective population. The prospective 
population performed the assessments both at BL (close to 
LCIG start) and at each follow-up visit, while most of the 
assessments were not performed close to LCIG start for the 
retrospective population. Therefore, we show in Table 4 the 
results of the prospective population and in Supplementary 
Table 1 those of the retrospective population.
The PDQ-39 showed significant improvements at V2 
(mean score 64.7 ± 25.4; p < 0.001) and at V3 (mean 
score 67.3 ± 26.4; p < 0.05) compared to BL (mean score 
72.3 ± 23.8) (Table 4).
Table 2  Use of antiparkinsonian medications before and during LCIG at each visit
Data presented in mean ± standard deviation (SD) or number (%)
LCIG levodopa/carbidopa intestinal gel, PD Parkinson’s disease, SC subcutaneous
Antiparkinso-
nian medica-
tions
Before LCIG start (N = 145) Visit 1 (N = 145) Visit 2 (N = 129) Visit 3 (N = 115)
N (%) Daily 
dose (mg) 
mean ± SD
N (%) Daily dose(mg) 
mean ± SD
N (%) Daily dose 
(mg),
mean ± SD
N (%) Daily dose (mg) 
mean ± SD
Oral levodopa 140 (96.6%) 818.74 ± 404.4 5 (3%)—
during the 
day
34 (23%)—
at night
150.0 ± 70.7 
during the day 
160.3 ± 72.5 
at night
4 (3%)—
during the 
day
30 (23%)—
at night
475.0 ± 518.8 
during the day 
164.2 ± 56.3 
at night
4 (3%)—
during the 
day
30 (26%)—
at night
137.5 ± 75.0 
during the day
186.7 ± 73.0 at 
night
Dopamine 
agonists
93 (64.1%) 6.38 ± 5.6 42 (29%) 5.6 ± 3.8 39 (30%) 5.1 ± 3.3 28 (24%) 6.6 ± 5.6
COMT inhibi-
tors
64 (44.1%) 590.7 ± 337.4 16 (11%) 253.1 ± 105.6 16 (12%) 215.6 ± 67.6 14 (12%) 196.4 ± 69.2
MAO inhibitors 21 (14.5%) 2.33 ± 3.31 5 (3%) 3.6 ± 3.9 5 (4%) 5.8 ± 5.07 5 (4%) 3.6 ± 3.9
Amantadine 25 (17.2%) 190.6 ± 112.6 8 (6%) 237.5 ± 91.6 12 (9%) 200.0 ± 95.3 10 (9%) 220.0 ± 113.5
Fig. 2  UPDRS-Part IV mean subscores at baseline/V1 (N = 139), V2 
(N = 129) and V3 (N = 115)
Fig. 3  Distribution of UPDRS-
IV Item 39 at Visit 2 (V2) 
and Visit 3 (V3) compared to 
baseline or V1
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Significant improvement in PDSS-2, GFQ and QUIP-
RS was also observed across all study visits. Among the 
QUIP-RS sub-items, sexual behavior, eating, and medi-
cation use showed a significant improvement compared 
to baseline only in the prospective population. The RSS 
for caregiver burden assessment did not show significant 
changes during the study compared to BL. The corre-
sponding ANOVA analysis for repeated measurement con-
firmed these results except for GFQ and QUIP-Medication 
use (Table 4).
Moreover, the clinicians considered 96% of the patients as 
“improved” since the first visit while only in 4% of the cases 
they reported a clinical worsening. Similarly, the patients’ 
judgment on their QoL was “very good” or “satisfactory” in 
91% of the cases at the last visit with a positive trend across 
the study (Fig. 4).
Secondary efficacy analysis
The sub-analyses according to age, disease duration, 
and time since infusion (< 1 year vs ≥ 1 year) showed 
that, compared to BL, there was a significant improve-
ment at V2 and V3 of the UPDRS II score during “ON” 
(respectively, p = 0.001 and p = 0.006) and at V3 of the 
UPDRS IV total score (p = 0.02) in patients with shorter 
( ≤ 13 years) compared with those with longer PD dura-
tion ( > 13 years). A significant improvement was observed 
at V2 of the UPDRS-I in OFF (p = 0.043) in patients 
aged ≤ 70 years; on the contrary, the same patients showed 
a significant worsening at V3 in UPDRS-IV total score 
(p = 0.024), UPDRS-IV item 32 (p = 0.02), and UPDRS-IV 
item 33 (p = 0.011) compared with those being more than 
70 years old, as reported in Table 5. Moreover, comparison 
based on the time since infusion, both at V2 and at V3, did 
Table 3  Complications of therapy (UPDRS IV), UPDRS-I, ADL and H&Y stage at baseline (before LCIG treatment) and at each follow-up 
visit, without LOCF
ADL activities of daily living, BL baseline, LCIG levodopa/carbidopa intestinal gel, SD standard deviation; UPDRS, United Parkinson’s Disease 
Rating Scale
BL mean score 
( ± SD) (Range)
N Visit 2 N Visit 3 N Reduction 
at V3 vs 
BL
*p value at V2 
vs BL
**p value at V3 
vs BL
p ANOVA 
for repeated 
measures
UPDRS IV total 
score (Items 
32–42)
8.2 (3.27) (0–18) 134 4.7 (2.88) (0–14) 124 4.9 (3.12) (0–14) 112 − 40% * < 0.001 
** < 0.001
 < 0.001
Dyskinesia dura-
tion (Item 32)
1.8 (1.04) (0–4) 134 1.2 (0.89) (0–4) 127 1.3 (1.02) (0–4) 113 − 28% * < 0.001 
** < 0.001
 < 0.001
Dyskinesia dis-
ability (Item 
33)
1.5 (1.11) (0–4) 133 0.9 (1.02) (0–4) 124 0.9 (1.01) (0–4) 112 − 40% * < 0.001 
** < 0.001
 < 0.001
Painful dyskine-
sia (Item 34)
0.8 (0.97) (0–4) 133 0.4 (0.69) (0–4) 124 0.4 (0.73) (0–4) 112 − 50% * < 0.001 
** < 0.001
 < 0.001
Presence of early 
morning dysto-
nia (Item 35)
58 (44%) (0–1) 133 35 (28%) 127 28 (25%) 113 − 43% *0.002 
** < 0.001
 < 0.001 
(Logit)
OFF time dura-
tion (Item 39)
2.0 (0.81) (0–4) 137 0.9 (0.69) (0–3) 127 1.0 (0.75) (0–3) 114 − 50% * < 0.001 
** < 0.001
 < 0.001
UPDRS I total score
OFF 6.8 (4.75) (0–16) 79 5.9 (3.86) (0–16) 81 6.0 (3.71) (1–16) 65 − 12% *0.054 0.006
ON 4.3 (3.08) (0–12) 96 3.6 (2.71) (0–12) 126 3.8 (2.78) (0–12) 110 − 12% **0.055 0.008
UPDRS II (ADL) 
total score
 OFF 29.2 (9.63) (0–48) 97 25.7 (8.49) 
(8–43)
86 25.5 (8.76) 
(8–46)
72 − 13% * < 0.001 
**0.003
 < 0.001
ON 18.2 (9.39) (0–39) 111 16.2 (8.49) 
(1–43)
127 16.2 (8.45) 
(1–34)
109 − 11% *0.003 **0.078  < 0.001
UPDRS V (Hoehn and Yahr)
OFF  3.99 (0.82) (2–5) 120  3.59 (0.85) 
(1–5)
 100  3.7 (0.81) (2–5)  88  − 7%  *< 0.001 
**0.003
 < 0.001
ON 3.07 (0.75) (1–5) 135 2.72 (0.77) (0–5) 128 2.77 (0.83) (0–5) 115 − 10% * < 0.001 
** < 0.001
 < 0.001
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not show differences in the majority of the UPDRS items 
except for a significant improvement in UPDRS-I ON 
(p = 0.036 and p = 0.004) and in UPDRS-II ON (p = 0.012 
and p = 0.019), and in UPDRS-IV item 33 (p = 0.012 at 
V2) in patients with less than 1 year of LCIG infusion 
(Table 5).
Adverse events
Overall, 40 (27.6%) patients experienced one or more SAEs 
(Table 6). The most frequently reported SAE, among those 
reported with a frequency higher than 1%, during LCIG 
infusion period were pneumonia (2.8%), femur fracture and 
cardiac failure (2.1%), peripheral neuropathy (1.4%), wors-
ening of PD, fasciitis, and peritonitis (1.4% each). Only 8 out 
Table 4  Outcome of non-motor symptoms and PD-associated symptoms at baseline and after LCIG at each treatment visit
ADL, activities of daily living; BL, baseline; LCIG; levodopa/carbidopa intestinal gel; SD, standard deviation; UPDRS, United Parkinson’s Dis-
ease Rating Scale
*p value at V2 vs BL, **p value at V3 vs BL
Prospective population without LOCF Baseline/V1 
Mean ± SD
Visit 2 Mean ± SD Visit 3 Mean ± SD p vs baseline p ANOVA for 
repeated meas-
ures
PDQ-39 (score 0–156) 72.3 ± 23.8 64.7 ± 25.4* 67.3 ± 26.4** *p < 0.001 **p < 0.05  < .0.001
PDSS-2 (score 0–60) 25 ± 10.4 22.5 ± 9.9* 22.7 ± 10.1 *p < 0.01 0.016
GFQ (score 0–64) 29.7 ± 13.3 26.5 ± 13.1* 26.1 ± 12 *p < 0.05 0.079
QUIP-RS (score 0–112) 10.4 ± 16.6 7.8 ± 13* 7.1 ± 10.1* *p < 0.05 0.011
QUIP-gambling (score 0–16) 1.2 ± 3.3 0.9 ± 2.6 0.5 ± 1.7 NS 0.085
QUIP-sexual behavior 1.5 ± 2.8 1.1 ± 2.5* 1.2 ± 2.7 *p < 0.05 0.140
QUIP-buying 1.5 ± 3.2 1.1 ± 2.3 0.8 ± 1.8 NS 0.100
QUIP-eating 2.2 ± 4 1.8 ± 3.6 1.5 ± 3* *p < 0.05 0.051
QUIP-hobbism 1.3 ± 2.7 1.2 ± 26 1.3 ± 2.5 NS 0.815
QUIP-punding 1.3 ± 3.4 1 ± 2.6 0.7 ± 1.9 NS 0.128
QUIP-Medication use 1.4 ± 3.5 0.7 ± 2.1* 1.2 ± 3 *p < 0.01 0.093
RSS-2 (score 15–75) 40.2 ± 12.4 39 ± 13.3 38.3 ± 13 NS 0.237
RSS/personal distress 16.5 ± 5.5 16.1 ± 5.7 15.9 ± 5.6 NS 0.467
RSS/negative feeling 9.2 ± 3.6 8.9 ± 3.7 8.7 ± 3.5 NS 0.085
RSS/life upset 14.5 ± 5 14 ± 5.1 13.7 ± 5 NS 0.455
Fig. 4  Global efficacy of LCIG made by neurologists vs baseline (a) 
and patient ‘s judgement on LCIG therapy at each visit (b). a Neu-
rologist’s clinical judgement rated by a three-point scale. b Score var-
ied between 0 (very scarce) and 10 (very good) and grouped for the 
analysis as 0–2 very scarce, 3–5 unsatisfactory, 6–8 satisfactory, 9–10 
very good
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Table 5  Impact of age of the patient, duration of disease and of time since infusion on the UPDRS scores ANCOVA model
Variables in bold are statistical significant for at least p < 0.05
All population—ANCOVA model Visit 2—year 1 Visit 3—year 2
Mean change 95% confidence 
Interval
p value Mean  
change
95%  confidence 
interval
p value
UPDRS item 39
 Age ( <  = 70 vs > 70 years) 0.01 − 0.27 to 0.265 0.947 0.16 − 0.11 to 0.43 0.242
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 0.15 − 0.41 to 0.10 0.245 − 0.20 − 0.47 to 0.07 0.142
 Baseline 0.798 0.153
 Time since infusion (prospective vs retrospective) 0.05 − 0.21 to 0.31 0.694 0.14 − 0.13 to 0.40 0.302
UPDRS I ‘ON’
 Age ( <  = 70 vs > 70 years) 0.37 − 0.64 to 1.38 0.473 0.32 − 0.82 to 1.456 0.576
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 0.73 − 1.72 to 0.27 0.151 − 0.27 − 1.39 to 0.85 0.633
Baseline 0.001 0.046
 Time since infusion (prospective vs retrospective) − 1.12 − 2.16 to − 0.07 0.036 − 1.72 − 2.88 to − 0.56 0.004
UPDRS I ’OFF’
 Age ( <  = 70 vs > 70 years) − 1.47 − 2.89 to − 0.05 0.043 − 1.24 − 3.29 to 0.81 0.231
 Time since PD diagnosis ( <  = 13 vs > 13 years) 0.91 − 0.42 to 2.4125 0.177 − 0.04 − 1.91 to 1.84 0.967
 Baseline  < 0.001  < 0.001
 Time since infusion (prospective vs retrospective) − 1.16 − 2.47 to 0.15 0.081 − 1.20 − 3.01 to 0.60 0.187
UPDRS II ’ON’
 Age ( <  = 70 vs > 70 years) 1.10 − 1.59 to 3.78 0.420 1.23 − 1.65 to 4.11 0.399
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 4.59 − 7.30 to − 1.88 0.001 − 4.09 − 6.99 to − 1.19 0.006
 Baseline  < 0.001  < 0.001
 Time since infusion (prospective vs retrospective) − 3.52 − 6.25 to − 0.78 0.012 − 3.53 − 6.46 to − 0.59 0.019
UPDRS II ‘OFF’
 Age ( <  = 70 vs > 70 years) − 2.95 − 6.29 to 0.39 0.083 − 1.53 − 5.11 to 2.04 0.396
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 2.25 − 5.52 to 1.02 0.175 − 3.08 − 6.59 to 0.42 0.084
 Baseline  < 0.001  < 0.001
 Time since infusion (prospective vs retrospective) − 2.44 − 5.79 to 0.92 0.152 − 1.95 − 5.54 to 1.65 0.284
UPDRS IV (A + B)
 Age ( <  = 70 vs > 70 years) 0.32 − 0.72 to 1.36 0.545 1.18 0.16 to 2.21 0.024
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 0.89 − 1.93 to 0.15 0.094 − 1.22 − 2.24 to − 0.19 0.020
 Baseline 0.005  < 0.001
 Time since infusion (prospective vs retrospective) − 0.63 − 1.68 to 0.42 0.236 − 0.60 − 1.62 to 0.43 0.254
UPDRS Dyskinesia score: ITEM 32
 Age ( <  = 70 vs > 70 years) 0.19 − 0.13 to 0.50 0.246 0.41 0.06 to 0.76 0.020
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 0.13 − 0.45 to 0.18 0.591 − 0.23 − 0.58 to 0.11 0.186
 Baseline 0.001 0.015
 Time since infusion (prospective vs retrospective) − 0.09 − 0.41 to 0.23 0.591 0.02 − 0.32 to 0.37 0.895
UPDRS Dyskinesia score: ITEM 33
 Age ( <  = 70 vs > 70 years) 0.12 − 0.25 to 0.49 0.527 0.45 0.11 to 0.80 0.011
 Time since PD diagnosis ( <  = 13 vs > 13 years) − 0.11 − 0.49 to 0.26 0.544 − 0.14 − 0.48 to 0.21 0.443
 Baseline 0.050 0.081
 Time since infusion (prospective vs retrospective) − 0.48 − 0.85 to − 0.11 0.012 − 0.4 − 0.69 to 0.01 0.055
UPDRS Dyskinesia score: ITEM 34
 Age ( <  = 70 vs > 70 years) 0.021 − 0.22 to 0.25 0.899 0.06 − 0.19 to 0.30 0.658
 Time since PD diagnosis ( <  = 13 vs > 13 years) 0.06 − 0.18 to 0.29 0.636 − 0.13 − 0.38 to 0.12 0.300
 Baseline  < 0.001  < 0.001
 Time since infusion (prospective vs retrospective) − 0.14 − 0.38 to 0.09 0.232 0.02 − 0.23 to 0.27 0.873
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of 49 SAEs (16.3%) were related to PEG/J procedure or to 
device. (Table 6). In 12 out of 145 patients (8.3%) the AEs 
lead to discontinuation, as reported in Table 6. Fifty-four 
patients (37.2%) experienced PQCs; the most frequent were 
tube occlusion in 11 cases, dislocation of duodenal tube in 
7 cases and phytobezoar in 5 cases (Table 6).
Thirteen deaths (9%) occurred during the observational 
period, mainly for cardiac reasons (six cases). For 12 deaths, 
a reasonably possible relationship has been reported.
Discussion
Here, we report the final results from the largest cohort of 
patients with APD treated with LCIG in routine clinical 
practice from 14 Italian Movement Disorder Centers. The 
APD patients in this study were affected by motor fluctua-
tions and dyskinesia not optimally controlled by standard 
oral or transdermal therapies. The previously published 
interim analysis of this study showed a significant reduction 
in total daily OFF time after a mean of 1.4 years of LCIG 
therapy with a magnitude of improvement consistent with 
the results reported in previous studies [22].
Results from this final analysis of up to 8 years of LCIG 
treatment (with a mean duration of 3 years) showed signifi-
cant improvements on motor fluctuations, ADL and QoL. 
The magnitude of OFF reduction observed in our study is 
Table 6  Overall safety in the retrospective and prospective data col-
lection cohorts
N. of patients with SAEs 40 (27.6%)
Event by preferred term N. Events
 Pneumonia 4 (2.8%)
 Femur fracture 3 (2.1%)
 Cardiac failure 3 (2.1%)
 Cardiac arrest 2 (1.4%)
 Peripheral neuropathy 2 (1.4%)
 Worsening of PD 2 (1.4%)
 Peritonitis 2 (1.4%)
 Death 2 (1.4%)
 Fasciitis 2 (1.4%)
  Hip fracture 1 (0.7%)
 Humerus fracture 1 (0.7%)
 Cerebral haematoma 1 (0.7%)
 Headache 1 (0.7%)
 Hyperkinesia 1 (0.7%)
 Acute myocardial infarction 1 (0.7%)
 Gastric ulcer 1 (0.7%)
 Haematemesis 1 (0.7%)
 Inguinal hernia 1 (0.7%)
 Intestinal obstruction 1 (0.7%)
 Agitation 1 (0.7%)
 Visual hallucination 1 (0.7%)
 Suicide attempt 1 (0.7%)
 Abnormal weight loss 1 (0.7%)
 Hypoglycemia 1 (0.7%)
 Acute pulmonary oedema 1 (0.7%)
 Pulmonary embolism 1 (0.7%)
 Anemia 1 (0.7%)
 Deep vein thrombosis 1 (0.7%)
Related to PEG/J procedure or to device
 Wrong technique in drug usage process 2 (1.4%)
 Gastrostomy tube site complication 1 (0.7%)
 Pyrexia 1 (0.7%)
 Administration site infection 1 (0.7%)
 Stoma site infection 1 (0.7%)
 Device occlusion 1 (0.7%)
 Medical device complication 1 (0.7%)
Total SAEs 49
 AEs leading to discontinuation N. patients
 Any AE leading to discontinuation 12 (8.3%)
 Device occlusion/device complication 2 (1.4%)
 Abnormal weight loss/hypoglycemia 2 (1.4%)
 Fasciitis 2 (1.4%)
 Peripheral sensory neuropathy 2 (1.4%)
 Cardiac arrest 1 (0.7%)
 Peritonitis 1 (0.7%)
 Hallucination, visual 1 (0.7%)
 Acute pulmonary oedema 1 (0.7%)
Table 6  (continued)
N. of patients with SAEs 40 (27.6%)
Product quality complaints during the study
 PQC experienced 54 (37.2%)
Event by preferred term N. Events
 Complaints associated with an adverse events 43 (29.7%)
 Complaints associated with an ADR 29 (20%)
 Complaints associated with a SAE 14 (9.7%)
Risks of PEG insertion 4 (2.8%)
 Immediate peristomal infections 2
 Bleedings and injury of internal organs 1
 Infections including peritonitis and pneumoperitoneum 1
Device Complications (Infusion system) 30 (20.7%)
 Accidental removal of PEG tube 2
 Tube occlusion 11
 Dislocation of duodenal tube 7
 Tube rupture, accidental removal, device leakage 5
 Phytobezoar 5
Surgical procedure 13 (9%)
 Encrusted dressing 1
 Signs of inflammation 3
 Granulation tissue 9
 Pump complication/rupture
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in agreement with the recently published data, where OFF 
reductions varied from 48 to 67% [8, 12, 20, 21, 23–25].
Moreover, the high percentage of patients reporting a 
UPDRS-IV item-39 score between 0 and 1 during LCIG 
infusion (approximately 80% at each visit) is also in line 
with the recently reported data from the PREDICT cross-
sectional study where the percentage for this score was 81% 
for patients treated with LCIG and only 17% in patients 
treated with oral standard PD therapies [26]. The clinical rel-
evance of this finding is further supported by the significant 
improvement of all UPDRS IV items related to dyskinesia 
and the total score of UPDRS IV.
The results of previous clinical studies on LCIG infusion 
have already indicated that this is an effective therapeutic 
strategy for improvements of motor symptoms (reduction in 
OFF time, increase in ON time without disabling dyskinesia, 
reduction of troublesome dyskinesia) [17, 27], non-motor 
symptoms (somnolence, fatigue, cardiovascular and urinary 
function, tremor at rest), and QoL [10, 28–30].
We observed significant improvements in UPDRS II for 
ADL, comparable to those reported in a 12-month prospec-
tive observational study including APD patients treated with 
LCIG as they start presenting with motor complications, 
having either 2–4 h of OFF time or 2 h of dyskinesia daily. 
In this study, patients experienced significant improvements 
from baseline in non-motor symptoms, with corresponding 
improvements in ADL up to 12 months [13].
Significant improvements compared to baseline were 
observed in the prospective population for QoL assessed by 
PDQ-39, quality of sleep assessed by PDSS-2, gait and bal-
ance disorders assessed by GFQ, and compulsive behavior 
by QUIP-RS with a significant impact on sexual behavior, 
eating, and medication use habit. A significant efficacy on 
these non-motor complications was previously also reported 
by Fasano et al. in a small group of patients treated with 
LCIG for 24 months [31]. Our results on sleep are in line 
with previously published data showing that LCIG improved 
the quality of sleep and produced a less fragmented sleep 
pattern measured by polysomnography after 6 months of 
therapy [32, 33].
It is interesting to note that in addition to the already 
established efficacy on motor and non-motor symptoms, 
there are clinically meaningful data regarding the positive 
effect of LCIG on axial symptoms. In fact, it has recently 
been reported in a retrospective study on 32 advanced PD 
patients, that LCIG has a favorable effect on freezing of gait 
(FoG), mainly represented by Pseudo-ON FoG and OFF-
type-FoG [25, 34]. Moreover, LCIG was shown to be effec-
tive in seven PD patients with prominent episodes of freez-
ing refractory to oral therapy [35].
In the sub-analyses of this study, we observed that 
patients with a shorter PD duration ( ≤ 13 years) had a bet-
ter outcome on motor complications and ADL compared to 
patients with a longer PD duration, while the age is discri-
minant only for motor complications which are slightly more 
disabling in younger compared to older patients.
The finding that patients with shorter disease duration had 
a greater efficacy in ADL is in line with the results obtained 
in the MONOTREAT study, where ADL score was sig-
nificantly improved starting from 3 months of treatment in 
patients with 13 years of PD duration and with short daily 
OFF time period (2–4 h) or dyskinesia period (2 h of trou-
blesome or non-troublesome dyskinesia) [13].
These evidences strongly suggest that, in advanced PD 
patients, early treatment with LCIG should be carefully and 
promptly evaluated to improve motor complications and 
daily living activities.
The safety results were consistent with the established 
profile of LCIG [30, 21, 36, 37]. The percentage of SAEs 
was in the range of the adverse drug reactions reported in the 
complete GLORIA observational registry [24], with device 
and procedure-related events more frequently reported. 
These observations must be taken into consideration on the 
necessity for close monitoring in the immediate post PEG/J 
positioning period and in the long-term follow-up.
This is the first Italian study with data from a large 
population followed for a long period of time. Since this 
investigation was observational, with the collection of data 
recorded during routine medical care, we consider these 
outcomes to be close to “real-world’ clinical practice and 
consistent with results generated in controlled short-term 
clinical studies. The mean treatment period in this cohort 
was approximately 3 years; clinical outcomes were fol-
lowed through 24 months of follow-up in this cohort of 145 
patients with APD to assess the benefits of LCIG infusion 
therapy for up to 8 years of treatment.
Limitations and strengths
Due to the partly retrospective design, many questionnaires 
and scales included in the protocol were not available at 
baseline especially in patients already in treatment with 
LCIG for more than 1 year. Therefore, the questionnaires 
with baseline assessment were available only in the smaller 
sample represented by the prospective population.
Since this was an observational study with the use of 
LCIG in routine care, the outcomes may be considered to 
be close to the real-world clinical practice, even if in the 
absence of a true control group.
Further limitation of this study is the fact that the results 
are not corrected for the levodopa equivalent daily dose of 
concomitant oral/transdermal antiparkinsonian medications. 
Although the use of concomitant medications was reduced 
after LCIG start, patients were still taking some antipar-
kinsonian or antidyskinetic during the study; therefore, 
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improvements in dyskinesias and fluctuations may be also 
due an adjunctive effect.
The sub-analyses took into account the age of patients at 
the enrollment and not the age at LCIG implant, considering 
that age at treatment initiation is another important aspect in 
LCIG selection criteria. This would have allowed a compari-
son with the results obtained in an interesting prospective, 
open-label study in 28 patients with APD treated with LCIG 
for a mean treatment period of 24 months. In that study, 
younger age at operation and absence or presence of mild 
psychiatric/behavioral symptoms were positive predictive 
factors in selecting the best candidates for LCIG therapy 
[23].
Conclusion
In conclusion, these results confirm that treatment with 
LCIG in the long term produces clinically significant 
improvements on motor function, non-motor symptoms, 
including sleep and impulsive disorders, and ADL in PD 
patients not optimally controlled by oral/transdermal thera-
pies. This study also suggested a greater improvement in 
motor fluctuation and in ADL in advanced PD patients 
treated earlier since PD onset. Adverse effects and complica-
tions have been observed during the study period; therefore, 
the proper indications for LCIG should be always taken into 
account for the selection of a patient, considering the benefit 
against safety issues.
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